Comparison of Arbutus Biopharma Corporation (ABUS) and Eidos Therapeutics Inc. (NASDAQ:EIDX)

As Biotechnology businesses, Arbutus Biopharma Corporation (NASDAQ:ABUS) and Eidos Therapeutics Inc. (NASDAQ:EIDX), are affected by contrast. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arbutus Biopharma Corporation 5.19M 26.96 73.35M -1.81 0.00
Eidos Therapeutics Inc. N/A 0.00 43.58M -1.14 0.00

Table 1 highlights Arbutus Biopharma Corporation and Eidos Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Arbutus Biopharma Corporation and Eidos Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Arbutus Biopharma Corporation -1,413.29% -72.9% -32.3%
Eidos Therapeutics Inc. 0.00% 0% 0%

Liquidity

Arbutus Biopharma Corporation has a Current Ratio of 11.4 and a Quick Ratio of 11.4. Competitively, Eidos Therapeutics Inc.’s Current Ratio is 28.1 and has 28.1 Quick Ratio. Eidos Therapeutics Inc.’s better ability to pay short and long-term obligations than Arbutus Biopharma Corporation.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Arbutus Biopharma Corporation and Eidos Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Arbutus Biopharma Corporation 0 0 0 0.00
Eidos Therapeutics Inc. 0 0 2 3.00

Competitively the average price target of Eidos Therapeutics Inc. is $31.33, which is potential 17.12% upside.

Insider and Institutional Ownership

Roughly 43.8% of Arbutus Biopharma Corporation shares are owned by institutional investors while 31.5% of Eidos Therapeutics Inc. are owned by institutional investors. Arbutus Biopharma Corporation’s share owned by insiders are 3.1%. On the other hand, insiders owned about 61.8% of Eidos Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arbutus Biopharma Corporation 10.17% 20.33% -4.1% -50.11% -17.01% 15.93%
Eidos Therapeutics Inc. 6.3% 50.7% 26.03% 32.28% 0% 33.72%

For the past year Arbutus Biopharma Corporation was less bullish than Eidos Therapeutics Inc.

Summary

Eidos Therapeutics Inc. beats Arbutus Biopharma Corporation on 8 of the 10 factors.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.